Evolution and control of COVID-19 epidemic in Hong Kong

SC Wong, AKW Au, JYC Lo, PL Ho, IFN Hung, KKW To… - Viruses, 2022 - mdpi.com
Hong Kong SAR has adopted universal masking, social distancing, testing of all
symptomatic and high-risk groups for isolation of confirmed cases in healthcare facilities …

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission …

CKH Wong, ICH Au, KTK Lau, EHY Lau… - The Lancet Infectious …, 2022 - thelancet.com
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: A systematic review and meta-analysis

C Chen, J Fang, S Chen, MJN Rajaofera, X Li… - BMC Infectious …, 2023 - Springer
Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …

D2BOF-COVIDNet: A Framework of Deep Bayesian Optimization and Fusion-Assisted Optimal Deep Features for COVID-19 Classification Using Chest X-ray and MRI …

A Hamza, MA Khan, M Alhaisoni, A Al Hejaili… - Diagnostics, 2022 - mdpi.com
Background and Objective: In 2019, a corona virus disease (COVID-19) was detected in
China that affected millions of people around the world. On 11 March 2020, the WHO …

Remdesivir significantly reduces SARS‐CoV‐2 viral load on nasopharyngeal swabs in hospitalized patients with COVID‐19: A retrospective case–control study

A Biancofiore, A Mirijello, MA Puteo… - Journal of Medical …, 2022 - Wiley Online Library
Remdesivir is a broad‐spectrum antiviral agent able to inhibit the RNA polymerase of SARS‐
CoV‐2. At present, studies focusing on the effect of remdesivir on viral load (VL) are few and …

A CNN‐Based Chest Infection Diagnostic Model: A Multistage Multiclass Isolated and Developed Transfer Learning Framework

MU Ali, KD Kallu, H Masood, U Tahir… - … Journal of Intelligent …, 2023 - Wiley Online Library
In 2019, a deadly coronaviral infection (COVID‐19) that infected millions of people globally
was detected in China. This fatal virus affects the respiratory system and currently spreads to …

Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID‐19: a self‐controlled case series study

CKH Wong, ICH Au, WY Cheng… - Alimentary …, 2022 - Wiley Online Library
Summary Background and Aim To investigate and quantify the risks of AKI and ALI
associated with remdesivir use, given the underlying diseases of SARS‐CoV‐2 infection …

Optimal timing of remdesivir initiation in hospitalized patients with coronavirus disease 2019 (COVID-19) administered with dexamethasone

CKH Wong, KTK Lau, ICH Au, X Xiong… - Clinical Infectious …, 2022 - academic.oup.com
Background Evidence is lacking about any additional benefits of introducing remdesivir on
top of dexamethasone, and the optimal timing of initiation. Methods In a territory-wide cohort …

Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation

S Padilla, K Polotskaya, M Fernández… - Journal of …, 2022 - academic.oup.com
Objectives To assess the benefits of remdesivir in hospitalized COVID-19 patients receiving
combined immunomodulatory therapy (CIT) with dexamethasone and tocilizumab. Methods …

Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study

CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling… - medRxiv, 2022 - medrxiv.org
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …